Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis Clinical Trial

— COMET  

Official title:

COMET: Correlating Outcomes With Biochemical Markers to Estimate Time-progression in IPF. A Prospective, Multi-Center, Longitudinal Follow up Study of Subjects With Idiopathic Pulmonary Fibrosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01071707
• Other study ID #: COMET
• Secondary ID: 1RC2HL101740-01
• Status: Completed
• Phase: N/A
• First received: February 18, 2010
• Last updated: October 16, 2012
• Start date: December 2009
• Est. completion date: August 2012

Study information

• Verified date: November 2009
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Study purpose:

The disease course of idiopathic pulmonary fibrosis (IPF) is variable. During the course of the disease some patients will get better, some will stay the same, and others will get worse. Currently doctors do not have any way to predict an individual patients disease course. The purpose of this study is to determine if 'biomarkers' such as proteins or genes isolated at the time of diagnosis can be used to predict the disease course. These 'biomarkers' will be obtained from samples of blood, from a procedure call a bronchoscopy, and in some patients from extra tissue obtained by a surgical lung biopsy.

Description:

The objectives of this study are as follows:

Specific Aim 1: Assemble a network of clinical centers to procure biologic samples from subjects with recently diagnosed IPF and follow these subjects for at least 48 weeks. Specific Aim 2: Correlate and integrate biologically plausible biomarkers of disease activity obtained from multiple compartments (SLB, BAL, TBB, blood) from the same subject with longitudinal measures of disease progression (change in forced vital capacity, change in diffusion capacity for carbon monoxide, acute exacerbation of pulmonary fibrosis, and death).

General Study Design This study will take place in two phases. During the first phase of the study we will identify and collect baseline specimens from subjects with either suspected or recently diagnosed (within 48 months) IPF. During the second phase of the study subjects with IPF will be followed from between 48 and 80 weeks. Subjects will be followed until the end of study (2 year grant award) or until they meet any part of a composite endpoint (death, acute exacerbation of IPF, relative decline in FVC of at least 10% or DLCO of 15%). This is a prospective cohort study. There is no treatment prescribed or studied as part of this prospective cohort study. Subjects are able to utilize any treatments prescribed by their physician, including participation in clinical trials as long as they are able to comply with the follow up schedule in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: August 2012
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Suspected or confirmed diagnosis of IPF

2. Age 35 - 80 years inclusive

3. Ability to understand and provide informed consent

Exclusion Criteria:

1. Confirmed diagnosis of IPF at the study center more than 4 years prior to screening

2. Environmental exposure (occupational, environmental, drug, etc) felt by the principal investigator (PI) to be the etiology of the interstitial disease

3. Diagnosis of collagen-vascular conditions (according to the published American College of Rheumatology criteria)

4. Forced expiratory volume in 1 second (FEV1)/FVC ratio < 0.60 at screening (postbronchodilator)

5. Significant bronchodilator response on screening spirometry, defined as a change in FEV1 = 12% and absolute change > 200 mL OR change in FVC = 12% and absolute change > 200 mL

6. Evidence of active infection at screening

7. Listed for lung transplantation at time of screening

8. Unstable or deteriorating cardiac disease at screening

9. Myocardial infarction, coronary artery bypass, or angioplasty within 6 months of screening

10. Unstable angina pectoris or congestive heart failure requiring hospitalization within 6 months of screening

11. Uncontrolled arrhythmia at screening

12. Severe uncontrolled hypertension at screening

13. Known HIV or hepatitis C at screening

14. Known cirrhosis or chronic active hepatitis at screening

15. Active substance and/or alcohol abuse at screening

16. Subjects who are pregnant or breastfeeding at screening

17. Women of childbearing potential who are not using a medically approved means of contraception at screening

18. Known bleeding abnormality that would preclude the performance of transbronchial lung biopsy

19. Prothrombin time, INR > 1.5, Partial Thromboplastin Time (PTT) > 45 at time of screening, platelets < 100,000/mm3

20. Any condition other than IPF that, in the opinion of the site PI, is likely to result in the death of the subject within the next year

21. Any condition that, in the judgment of the site PI, might cause participation in this study to be detrimental to the subject or that the site PI deems makes the subject a poor candidate

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	National Jewish Medical and Research Center	Denver	Colorado
United States	University of California, Los Angeles	Los Angeles	California
United States	Vanderbilt University	Nashville	Tennessee
United States	Temple University	Philadelphia	Pennsylvania
United States	Brown University	Providence	Rhode Island
United States	University of California, San Francisco	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
University of Michigan	National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome is progression free survival as determined by time until any of: death, acute exacerbation of IPF, relative change in FVC (liters) of at least 10% or DLCO (ml/min/mmHg) of 15%.		Follow up visits after baseline, every 16 weeks for minimum of 40 weeks and maximum of 80 weeks	Yes